ZA985237B - Novel method of treatment. - Google Patents

Novel method of treatment.

Info

Publication number
ZA985237B
ZA985237B ZA9805237A ZA985237A ZA985237B ZA 985237 B ZA985237 B ZA 985237B ZA 9805237 A ZA9805237 A ZA 9805237A ZA 985237 A ZA985237 A ZA 985237A ZA 985237 B ZA985237 B ZA 985237B
Authority
ZA
South Africa
Prior art keywords
treatment
novel method
novel
Prior art date
Application number
ZA9805237A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of ZA985237B publication Critical patent/ZA985237B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9805237A 1997-06-18 1998-06-17 Novel method of treatment. ZA985237B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
ZA985237B true ZA985237B (en) 2000-02-17

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9805237A ZA985237B (en) 1997-06-18 1998-06-17 Novel method of treatment.

Country Status (30)

Country Link
EP (1) EP0999837A1 (enExample)
JP (1) JP2002504138A (enExample)
KR (1) KR20010013843A (enExample)
CN (1) CN1133431C (enExample)
AP (1) AP1287A (enExample)
AR (2) AR012997A1 (enExample)
AU (1) AU8216398A (enExample)
BG (1) BG104059A (enExample)
BR (1) BR9810444A (enExample)
CA (1) CA2294141A1 (enExample)
CO (1) CO4940454A1 (enExample)
DZ (1) DZ2521A1 (enExample)
EA (1) EA004800B1 (enExample)
GB (1) GB9712866D0 (enExample)
HU (1) HUP0003260A3 (enExample)
ID (1) ID23951A (enExample)
IL (1) IL133143A0 (enExample)
IN (1) IN189723B (enExample)
MA (1) MA26511A1 (enExample)
NO (1) NO996265L (enExample)
OA (1) OA11517A (enExample)
PE (1) PE104499A1 (enExample)
PL (1) PL343123A1 (enExample)
SK (1) SK179399A3 (enExample)
TR (1) TR199903095T2 (enExample)
TW (1) TW587937B (enExample)
UA (1) UA70299C2 (enExample)
UY (1) UY25050A1 (enExample)
WO (1) WO1998057636A1 (enExample)
ZA (1) ZA985237B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
HRP20010773B1 (en) 1999-04-23 2005-06-30 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
SI1133312T1 (sl) * 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
CA2503117C (en) 2002-11-08 2010-12-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1103590C (zh) * 1993-09-15 2003-03-26 三共株式会社 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
JPH11510508A (ja) * 1995-08-10 1999-09-14 ワーナー−ランバート・コンパニー インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法
PT859608E (pt) * 1995-09-18 2004-06-30 Ligand Pharm Inc Tratamento de niddm com agonistas de rxr

Also Published As

Publication number Publication date
PL343123A1 (en) 2001-07-30
NO996265D0 (no) 1999-12-17
AR015894A1 (es) 2001-05-30
PE104499A1 (es) 2000-01-13
EA004800B1 (ru) 2004-08-26
SK179399A3 (en) 2000-11-07
TW587937B (en) 2004-05-21
DZ2521A1 (fr) 2003-02-08
HUP0003260A3 (en) 2001-12-28
HUP0003260A2 (hu) 2001-05-28
CN1133431C (zh) 2004-01-07
WO1998057636A1 (en) 1998-12-23
CA2294141A1 (en) 1998-12-23
IL133143A0 (en) 2001-03-19
ID23951A (id) 2000-06-08
CN1260715A (zh) 2000-07-19
KR20010013843A (ko) 2001-02-26
AR012997A1 (es) 2000-11-22
TR199903095T2 (xx) 2000-08-21
NO996265L (no) 1999-12-17
BG104059A (en) 2000-10-31
OA11517A (en) 2004-02-04
AU8216398A (en) 1999-01-04
AP1287A (en) 2004-06-26
AP9901718A0 (en) 1999-12-31
IN189723B (enExample) 2003-04-19
MA26511A1 (fr) 2004-12-20
JP2002504138A (ja) 2002-02-05
EA200000042A1 (ru) 2000-08-28
BR9810444A (pt) 2000-09-05
UY25050A1 (es) 2000-09-29
CO4940454A1 (es) 2000-07-24
EP0999837A1 (en) 2000-05-17
GB9712866D0 (en) 1997-08-20
UA70299C2 (en) 2004-10-15

Similar Documents

Publication Publication Date Title
ZA200108446B (en) Novel method of treatment.
GB9617780D0 (en) Method of treatment
ZA986363B (en) Novel method of treatment.
GB9712866D0 (en) Novel method of treatment
GB9605828D0 (en) Treatment method
GB9707693D0 (en) Novel method of treatment
ZA986364B (en) Novel method of treatment.
ZA986365B (en) Novel method of treatment.
GB9710990D0 (en) Modification process
ZA977867B (en) Method of treatment.
GB9714841D0 (en) Treatment method
ZA973988B (en) Method of treatment
ZA200007396B (en) Method of treatment.
AP2005003432A0 (en) Novel method of treatment.
ZA985236B (en) Novel method of treatment.
ZA985235B (en) Novel method of treatment.
ZA985238B (en) Novel method of treatment.
GB9717399D0 (en) Method of treatment
GB9724289D0 (en) Method of treatment
ZA963472B (en) Method of treatment.
GB9703102D0 (en) Treatment method
EG24158A (en) Novel method of treatment
GB9824789D0 (en) Novel method of treatment
GB9824871D0 (en) Novel method of treatment
GB9824790D0 (en) Novel method of treatment